FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096001845> ?p ?o ?g. }

• W2096001845 endingPage "4094" @default.
• W2096001845 startingPage "4090" @default.
• W2096001845 abstract "Abstract Purpose: As first-generation small-molecule vascular disrupting agents (VDA) have begun to enter clinical trials, second-generation agents are under active development. One such agent is the combretastatin A4 disodium phosphate (CA4P) analogue OXi4503 (CA1P). Experimental Design: C3H/HeJ mice bearing KHT sarcomas were treated with CA4P and OXi4503 and the effect on tumor vasculature was determined by evaluating the extent of vascular shutdown (Hoechst-33342 vessel staining) and tumor perfusion inhibition (dynamic contrast-enhanced magnetic resonance imaging). Dynamic contrast-enhanced magnetic resonance imaging and tumor necrosis end points also were used to examine the pathophysiologic tumor effects following repeated exposures to these agents. Results: Single doses of either agent (CA4P, 100 mg/kg; OXi4503, 25 mg/kg) resulted in an 80% to 90% reduction in tumor perfusion 4 hours after treatment. Whereas recovery in tumor perfusion was observed 48 hours posttreatment, this recovery was significantly slower in mice treated with OXi4503. Tumors re-treated with either VDA 72 hours after the first drug exposure showed a similar reduction and recovery in tumor perfusion. Histologic evidence showed the presence of a smaller viable rim after exposure to OXi4503 than that observed after CA4P treatment. Furthermore, the extent of recovery of tumor necrosis 72 hours after drug treatment was less for OXi4053. Conclusions: The present studies show that the second-generation VDA OXi4503 possesses significant antivascular effects in solid tumors. Importantly, the vasculature of tumors of mice that had received an initial dose this agent was as responsive to a subsequent treatment." @default.
• W2096001845 created "2016-06-24" @default.
• W2096001845 creator A5001008875 @default.
• W2096001845 creator A5059454105 @default.
• W2096001845 date "2006-07-01" @default.
• W2096001845 modified "2023-09-27" @default.
• W2096001845 title "Effect of the Second-Generation Vascular Disrupting Agent OXi4503 on Tumor Vascularity" @default.
• W2096001845 cites W1493048246 @default.
• W2096001845 cites W1536644025 @default.
• W2096001845 cites W1538210794 @default.
• W2096001845 cites W1966726954 @default.
• W2096001845 cites W1992375630 @default.
• W2096001845 cites W2000970414 @default.
• W2096001845 cites W2016667215 @default.
• W2096001845 cites W2033285216 @default.
• W2096001845 cites W2037060916 @default.
• W2096001845 cites W2038145387 @default.
• W2096001845 cites W2040455477 @default.
• W2096001845 cites W2050777370 @default.
• W2096001845 cites W2057910790 @default.
• W2096001845 cites W2059927830 @default.
• W2096001845 cites W2061718399 @default.
• W2096001845 cites W2072290539 @default.
• W2096001845 cites W2073245509 @default.
• W2096001845 cites W2073460574 @default.
• W2096001845 cites W2085281191 @default.
• W2096001845 cites W2105412427 @default.
• W2096001845 cites W2148990197 @default.
• W2096001845 cites W2152574565 @default.
• W2096001845 cites W41770144 @default.
• W2096001845 cites W88448219 @default.
• W2096001845 doi "https://doi.org/10.1158/1078-0432.ccr-06-0163" @default.
• W2096001845 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16818709" @default.
• W2096001845 hasPublicationYear "2006" @default.
• W2096001845 type Work @default.
• W2096001845 sameAs 2096001845 @default.
• W2096001845 citedByCount "100" @default.
• W2096001845 countsByYear W20960018452012 @default.
• W2096001845 countsByYear W20960018452013 @default.
• W2096001845 countsByYear W20960018452014 @default.
• W2096001845 countsByYear W20960018452015 @default.
• W2096001845 countsByYear W20960018452016 @default.
• W2096001845 countsByYear W20960018452017 @default.
• W2096001845 countsByYear W20960018452018 @default.
• W2096001845 countsByYear W20960018452019 @default.
• W2096001845 countsByYear W20960018452020 @default.
• W2096001845 countsByYear W20960018452021 @default.
• W2096001845 countsByYear W20960018452022 @default.
• W2096001845 countsByYear W20960018452023 @default.
• W2096001845 crossrefType "journal-article" @default.
• W2096001845 hasAuthorship W2096001845A5001008875 @default.
• W2096001845 hasAuthorship W2096001845A5059454105 @default.
• W2096001845 hasConcept C126322002 @default.
• W2096001845 hasConcept C126838900 @default.
• W2096001845 hasConcept C142724271 @default.
• W2096001845 hasConcept C143409427 @default.
• W2096001845 hasConcept C146957229 @default.
• W2096001845 hasConcept C178596483 @default.
• W2096001845 hasConcept C17991360 @default.
• W2096001845 hasConcept C20418707 @default.
• W2096001845 hasConcept C2778275628 @default.
• W2096001845 hasConcept C2780035454 @default.
• W2096001845 hasConcept C503630168 @default.
• W2096001845 hasConcept C71924100 @default.
• W2096001845 hasConcept C84425145 @default.
• W2096001845 hasConcept C86803240 @default.
• W2096001845 hasConcept C95444343 @default.
• W2096001845 hasConcept C98274493 @default.
• W2096001845 hasConceptScore W2096001845C126322002 @default.
• W2096001845 hasConceptScore W2096001845C126838900 @default.
• W2096001845 hasConceptScore W2096001845C142724271 @default.
• W2096001845 hasConceptScore W2096001845C143409427 @default.
• W2096001845 hasConceptScore W2096001845C146957229 @default.
• W2096001845 hasConceptScore W2096001845C178596483 @default.
• W2096001845 hasConceptScore W2096001845C17991360 @default.
• W2096001845 hasConceptScore W2096001845C20418707 @default.
• W2096001845 hasConceptScore W2096001845C2778275628 @default.
• W2096001845 hasConceptScore W2096001845C2780035454 @default.
• W2096001845 hasConceptScore W2096001845C503630168 @default.
• W2096001845 hasConceptScore W2096001845C71924100 @default.
• W2096001845 hasConceptScore W2096001845C84425145 @default.
• W2096001845 hasConceptScore W2096001845C86803240 @default.
• W2096001845 hasConceptScore W2096001845C95444343 @default.
• W2096001845 hasConceptScore W2096001845C98274493 @default.
• W2096001845 hasIssue "13" @default.
• W2096001845 hasLocation W20960018451 @default.
• W2096001845 hasLocation W20960018452 @default.
• W2096001845 hasOpenAccess W2096001845 @default.
• W2096001845 hasPrimaryLocation W20960018451 @default.
• W2096001845 hasRelatedWork W1579129437 @default.
• W2096001845 hasRelatedWork W1968655487 @default.
• W2096001845 hasRelatedWork W2057475952 @default.
• W2096001845 hasRelatedWork W2096001845 @default.
• W2096001845 hasRelatedWork W2239006518 @default.
• W2096001845 hasRelatedWork W2413092364 @default.
• W2096001845 hasRelatedWork W2415133252 @default.
• W2096001845 hasRelatedWork W2441163238 @default.
• W2096001845 hasRelatedWork W2752653755 @default.

• next